Express Scripts, Inc. (NASDAQ:ESRX)
Provides pharmacy benefit management services, including retail drug card programs, mail pharmacy services, drug formulary management programs and other clinical management programs for HMOs, health insurers, third-party administrators and employers.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
hunter694
(27.41)
Submitted: 2/9/2012 6:37:28 PM :
Start Price:
$49.81
ESRX Score:
+0.57
I really hope the merger get's the approval of the FTC!
Recs
Recs
EBStroke
(< 20)
Submitted: 2/6/2012 8:05:32 PM :
Start Price:
$50.52
ESRX Score:
+0.84
negative news on merger with MedcoHealth Solutions (NYSE: MHS),
Recs
MHenage
(< 20)
Submitted: 2/1/2012 1:58:42 PM :
Start Price:
$52.08
ESRX Score:
-4.81
Positive free cash flow of nearly $450 million average per quarter in the last year. nuff said.
Recs
Hawk46
(< 20)
Submitted: 1/29/2012 10:06:19 PM :
Start Price:
$50.54
ESRX Score:
-3.82
Generics increasing.
Recs
sikiliza
(71.92)
Submitted: 1/25/2012 3:18:09 PM :
Start Price:
$52.51
ESRX Score:
-5.75
Baby boomers
Recs
hrmtcrb
(88.38)
Submitted: 10/22/2011 8:06:27 AM :
Start Price:
$39.35
ESRX Score:
+19.29
The expected merger with MHS coupled with the growing baby boom population and wider availability of generic alternatives to brand name medications should make this a winner for the next few years.
Recs
45mm
(< 20)
Submitted: 9/14/2011 3:17:54 PM :
Start Price:
$43.44
ESRX Score:
+3.71
Below 200 day moving avg. should rebound once merger takes place
Recs
StockDocStan
(< 20)
Submitted: 9/9/2011 10:46:31 AM :
Start Price:
$45.06
ESRX Score:
-2.57
With or without Medco, Express Scripts will be a long-term winner, and I don't see how that has been less than obvious lately for the market.
Recs
Jaxxs
(37.54)
Submitted: 7/21/2011 8:23:41 AM :
Start Price:
$56.65
ESRX Score:
-12.16
Drugs are good
Recs
BoiseKen
(94.94)
Submitted: 7/21/2011 7:17:28 AM :
Start Price:
$56.65
ESRX Score:
-12.16
They might get knocked down shortterm from the MHS deal, but longterm, I think they paid a great price for a longterm boost. Generic drugs going off patent along with MHS' individualized medicine and depth of skill make this a winner.
Recs
Recs
troym72
(37.90)
Submitted: 6/7/2011 2:05:04 PM :
Start Price:
$57.01
ESRX Score:
-15.39
Express Scripts is in a great position to take advantage of the aging population which will is in greater and greater need for regular maintenance medications, which falls right into their mail-order strategy. Increasing Revenue and EPS over the last 5 years shows that Express Scripts has the leadership and direction to keep growing for years to come.
Recs
Humle100
(95.68)
Submitted: 5/29/2011 2:34:06 AM :
Start Price:
$58.95
ESRX Score:
-14.59
Long term hold - predictability
Recs
stovkey1highdiv
(< 20)
Submitted: 5/10/2011 1:29:33 AM :
Start Price:
$59.21
ESRX Score:
-14.67
key03, no div
Recs
Vanheezy18
(82.08)
Submitted: 4/24/2011 9:22:14 PM :
Start Price:
$56.04
ESRX Score:
-10.98
ESRX will beat earnings tomorrow causing stock price to appreciate
Recs
csmoult
(< 20)
Submitted: 1/5/2011 11:34:03 AM :
Start Price:
$56.31
ESRX Score:
-16.34
Between 1993 and 1999 I invested a total of 28,700. In Express Scripts. From 1999 to the present I just sat on this stock. I now have 24,000 shares worth over 1.3 million.
In my opinion this is the ultimate buy-and-hold growth stock. Every time the price rises to $100 they split the stock making it more attractive to small investors. They have consistently grown the company by acquiring smaller competitors and seamlessly integrating them into the company's operation. Recently they have stood up to labor unions by shifting work away from areas where labor is hostile to them to areas where labor is willing to work with them.
Recs
daddybyday
(33.38)
Submitted: 11/10/2010 4:18:30 PM :
Start Price:
$52.15
ESRX Score:
-14.79
And yet another SMA crossover experiment.
Recs
fightingamish2
(< 20)
Submitted: 7/1/2010 3:42:21 PM :
Start Price:
$45.95
ESRX Score:
-21.42
great price, well positioned in its market, low PEGY ratio
Recs
CellBlock9
(96.16)
Submitted: 6/30/2010 9:34:03 PM :
Start Price:
$46.93
ESRX Score:
-23.35
S&P 5 stars
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 80 : 1 2 3 4 Next »